278 material Form 8-K filings that 243 companies we cover made with the SEC in May 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Abercrombie & Fitch reported first quarter fiscal 2024 results for the period ended May 4, 2024, with net sales of $1.0 billion, up 22% from last year, and diluted EPS of $2.14 versus $0.32 a year earlier. The company raised its full-year fiscal 2024 outlook to net sales growth of around 10% and an operating margin of around 14%, which replaces prior guidance.
Q1 net sales $1,020.7 million, up 22%; comparable sales up 21%; Abercrombie brands up 31%, Hollister brands up 12%
Operating income $130 million, operating margin 12.7%, up 860 basis points from 4.1% last year
Full-year outlook: net sales up around 10% (previously 4% to 6%); operating margin around 14% (previously around 12%)
RadNet reported first quarter 2024 revenue of $431.7 million, up 10.5% from a year earlier, and Adjusted EBITDA of $58.5 million, up 21.4%. The company raised its 2024 guidance ranges for revenue, Adjusted EBITDA and free cash flow, while still reporting a net loss attributable to common stockholders of $2.8 million for the quarter.
Total company revenue rose 10.5% to $431.7 million; Adjusted EBITDA rose 21.4% to $58.5 million for the quarter ended March 31, 2024.
GAAP net loss attributable to RadNet common stockholders was $2.8 million, or $(0.04) per share, versus a $21.0 million loss, or $(0.36) per share, a year earlier.
Imaging Center segment revenue guidance for 2024 was revised to $1,675 - $1,725 million from $1,650 - $1,700 million.
Cash and cash equivalents were $527.0 million at March 31, 2024, after a March common stock offering that raised net proceeds of approximately $219 million.
Universal Technical Institute reported fiscal 2024 second-quarter revenue of $184.2 million, up 12.4% from a year earlier, and net income of $7.8 million, up from $3.5 million. The company raised its full-year fiscal 2024 guidance for revenue, net income, diluted EPS and adjusted EBITDA, and gave initial fiscal 2025 projections that include revenue of nearly $800 million.
Q2 revenue of $184.2 million, up 12.4% from $163.8 million; diluted EPS of $0.14 versus $0.04
Fiscal 2024 revenue guidance raised to $720 million to $730 million from $710 million to $720 million
Fiscal 2024 net income guidance raised to $37 million to $41 million from $36 million to $40 million
Initial fiscal 2025 projections: revenue of nearly $800 million and adjusted EBITDA margin of approximately 15%
ScanSource reported third-quarter fiscal 2024 net sales of $752.6 million, down 15.0% year over year, and GAAP diluted EPS of $0.50, down from $0.83. The company lowered its full-year fiscal 2024 guidance for net sales, adjusted EBITDA and free cash flow was raised, and it announced a new $100 million share repurchase authorization.
Q3 net sales $752.6 million, down 15.0%; GAAP net income $12.8 million, down 39.7%
FY24 net sales outlook cut to at least $3.3 billion from at least $3.5 billion; adjusted EBITDA cut to at least $140 million from at least $155 million
FY24 free cash flow outlook raised to at least $275 million from at least $200 million
New $100 million share repurchase authorization; about $45 million remained under the prior authorization as of March 31, 2024
Adtalem Global Education (NYSE: ATGE) reported fiscal Q3 2024 revenue of $412.7 million, up 11.8%, and raised its fiscal 2024 revenue and adjusted EPS guidance. GAAP net income fell to $36.8 million from $45.9 million, but adjusted EPS rose to $1.50 from $1.13. Note: this 8-K is filed by Adtalem, not Covista Inc. (CVSA) as the request stated.
Revenue $412.7 million, up 11.8% from $369.1 million; total enrollment 85,809, up 7.8%
FY2024 revenue guidance raised to $1,560 million to $1,580 million from $1,520 million to $1,560 million
FY2024 adjusted EPS guidance raised to $4.80 to $5.00 from $4.55 to $4.75
Diluted GAAP EPS $0.93 vs $1.00 a year earlier; repurchased $91 million of shares
SPX Technologies reported first quarter 2024 revenue of $465.2 million, up from $399.8 million a year earlier, and GAAP diluted EPS of $1.05 versus $0.84. The company raised its full-year 2024 adjusted EPS guidance to $5.15 to $5.40 from $4.85 to $5.15, citing strong HVAC demand, which benefits shareholders as profit measures grew and the outlook improved.
Q1 2024 revenue $465.2 million vs. $399.8 million; net income $49.0 million vs. $42.8 million
Diluted EPS from continuing operations $1.05 vs. $0.84; adjusted EPS $1.25 vs. $0.93
Expedia Group reported first quarter 2024 revenue of $2.9 billion, up 8%, and a net loss of $135 million, narrower than the $145 million loss a year earlier. The company lowered its full-year guidance to mid to high single digit top line growth, citing a slower-than-expected recovery at Vrbo and gross bookings that rose only 3%.
Revenue was $2.9 billion, up 8% from the first quarter of 2023; gross bookings were $30.2 billion, up 3%
Net loss attributable to Expedia Group was $135 million versus $145 million a year earlier; adjusted EPS was $0.21 versus a loss of $0.20
Full-year guidance lowered to mid to high single digit top line growth, with margins relatively in line with last year
Repurchased about 5.7 million shares for about $786 million year-to-date
Curtiss-Wright reported first quarter 2024 sales of $713 million, up 13%, and adjusted diluted EPS of $1.99, up 30%. The company raised its full-year 2024 guidance for sales, operating income and diluted EPS, while the Naval & Power segment's profit fell on a naval contract adjustment.
Q1 2024 sales of $713 million, up 13%; reported operating income of $100 million, up 27%
Diluted EPS of $1.99 versus $1.48 a year earlier; adjusted diluted EPS up 30%
2024 diluted EPS guidance raised to $10.10 to $10.40 from $10.00 to $10.30; sales growth guidance raised to 5% to 7%
Naval & Power adjusted operating income fell 13% to $35 million due to an unfavorable naval contract adjustment
Laureate Education reported first-quarter 2024 revenue of $275.4 million, up 10% as reported but up 1% on an organic constant currency basis. Its net loss narrowed to $(10.8) million from $(26.8) million, while Adjusted EBITDA fell to $30.6 million from $33.5 million. The company raised its full-year 2024 revenue and Adjusted EBITDA guidance, citing more favorable currency rates.
Q1 2024 revenue $275.4 million, up 10% as reported and 1% on an organic constant currency basis
Net loss $(10.8) million vs. $(26.8) million a year earlier; loss per share $(0.07) vs. $(0.17)
Operating income $11.1 million vs. $15.6 million; Adjusted EBITDA $30.6 million vs. $33.5 million
2024 revenue now expected at $1,566 million to $1,581 million; Adjusted EBITDA at $446 million to $456 million
Digi International reported second fiscal quarter 2024 revenue of $108 million, down 3% from a year earlier, and net income of $4 million, down from $6 million. The company lowered its fiscal 2024 Adjusted EBITDA range and now projects revenue down 5% year over year, citing customers who are more cautious on second half demand and longer sales cycles.
Q2 revenue was $108 million, down 3%; diluted EPS was $0.11 versus $0.16, and adjusted diluted EPS was $0.49, flat year over year
Company accrued an approximate $6 million liability for pending litigation in the quarter
Fiscal 2024 revenue is projected to be down 5% year over year; Adjusted EBITDA range lowered slightly
Third quarter revenue guidance is $103 million to $107 million, with adjusted diluted EPS of $0.47 to $0.51
Corcept Therapeutics reported first quarter 2024 revenue of $146.8 million, up 39 percent from a year earlier, and net income of $27.8 million, compared with $15.9 million in the first quarter of 2023. The company raised its 2024 revenue guidance to $620 million to $650 million from $600 million to $630 million, which points to stronger expected sales for the year.
Q1 2024 revenue of $146.8 million vs. $105.7 million in Q1 2023; diluted EPS $0.25 vs. $0.14
2024 revenue guidance raised to $620 million to $650 million from $600 million to $630 million
Operating expenses rose to $117.3 million from $90.8 million, driven by clinical trial activity and commercial team expansion
Cash and investments were $451.0 million at March 31, 2024, up from $425.4 million at December 31, 2023
Vita Coco reported first quarter 2024 net sales up 2% to $112 million, with net income of $14 million, or $0.24 per diluted share, compared with $7 million, or $0.12, a year earlier. The company raised its full-year 2024 guidance to net sales of $500 million to $510 million and Adjusted EBITDA of $76 million to $82 million, but said higher ocean freight costs will weigh on gross margins starting in the second quarter.
Q1 2024 net sales rose 2% to $112 million, and gross margin rose to 42.2% from 30.7%.
Q1 2024 Adjusted EBITDA was $21 million, compared with $9 million in the same period of 2023.
2024 guidance: net sales of $500 million to $510 million, Adjusted EBITDA of $76 million to $82 million, and full-year gross margin of 37% to 39%.
TG Therapeutics reported first quarter 2024 total revenue of $63.5 million, up from $7.8 million a year earlier, and a net loss of $10.7 million, down from $39.2 million. The company raised its full-year 2024 U.S. BRIUMVI net product revenue target to $270 million to $290 million, from $220 million to $260 million previously.
Q1 2024 total revenue of $63.5 million, including a $12.5 million milestone payment tied to the first EU launch of BRIUMVI in Germany
Q1 2024 U.S. BRIUMVI net product revenue of $50.5 million; company targets approximately $65 million for Q2 2024
Net loss of $10.7 million, or $0.07 per share, versus $39.2 million, or $0.28 per share, in Q1 2023
Cash, cash equivalents and investment securities of $209.8 million as of March 31, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.